Twist Bioscience
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +136.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 14.8% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 50.7% | Better than 64% |
| Operating margin | -36.2% | Better than 10% |
| Net margin | -20.6% | Better than 12% |
| Return on equity | -16.4% | Better than 17% |
| Return on invested capital | -15.6% | Better than 15% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -29.0% | Better than 19% |
| 6-month return | 70.6% | Better than 98% |
| 12-month return (ex latest month) | 374.3% | Better than 100% |
| Distance below 52-week high | 53.0% | Better than 16% |
Financial Health B-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.6x | Better than 79% |
| Debt to assets | 11.8% | Better than 67% |
| Interest coverage | -7,177.1x | Better than 1% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 83.3% | Better than 63% |
| Upside to average target | 70.5% | Better than 76% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 111.62
- Open
- 108.39
- Day range
- 101.00 - 108.50
- Avg price
- 103.98
- Volume
- 3.38M
- Turnover
- 351.44M
- Turnover ratei
- 5.16%
- Volume ratioi
- 1.51
- Amplitudei
- 6.72%
- 52-week rangei
- 28.27 - 219.71
Valuation
- P/Ei
- -49.67
- P/E (TTM)i
- -49.67
- P/Bi
- 7.71
- EPSi
- -2.08
- Book value / shi
- 13.39
- Net profit
- -137.91M
- Net assets
- 888.04M
Share structure
- Market cap
- 6.85B
- Float capi
- 6.77B
- Shares out
- 66.30M
- Float sharesi
- 65.48M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2018-10-31
53.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-34.76M net over the window
Short interest
- Shares short
- 9.84M
- % of floati
- 14.83%
- Days to coveri
- 4.35
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Twist Bioscience (TWST)?
Twist Bioscience last traded at 103.32. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Twist Bioscience's market cap?
About 6.85B.
What is the P/E ratio of Twist Bioscience?
The trailing twelve-month P/E is -49.67. The Valuation tab shows it against the stock's own five-year range.
Does Twist Bioscience pay a dividend?
Twist Bioscience does not currently pay a regular dividend.
Is Twist Bioscience a buy according to analysts?
The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 130.25, which implies 26.1% upside from the current price. This is not investment advice.
What is Twist Bioscience's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Twist Bioscience a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:52:04 · For reference only, not investment advice and not tailored to your situation.
Twist Bioscience discussion 0 comments